What type of study is this?

August 16, 2025Open Access

The Natural Coagulation Inhibitors, Inflammation, and Thrombotic Risk in Sickle Cell Patients in Cameroon, an Analytical Cross-Sectionnal Study

View Full Paper

Ask AI

Bookmark

Authors

RTRomaric De Manfouo TuonoUniversité de Yaoundé I JLJosué Simo LouokdomUniversité des Montagnes IYI. YongUniversité de Yaoundé I

Discussion

Member takes

Implication

Analytical cross-sectional study finds high thrombotic risk linked to decreased coagulation inhibitors in sickle cell patients, indicating inflammation’s role.

Key Points

An elevated thrombotic risk of 65.34% was found in sickle cell patients, highlighting significant health concerns.
Inflammatory markers showed 100% of patients at risk elevated CRP levels, compared to none in the non-risk group.
Analytical cross-sectional study evaluated coagulation inhibitors and inflammation in sickle cell patients over one year.
Findings underscore the importance of monitoring coagulation inhibitors to reduce cardiovascular disease risk.

Cite This Study

Tuono et al. (2025) studied this question.

synapsesocial.com/papers/68a3669b0a429f797332c467 https://doi.org/10.21203/rs.3.rs-7345873/v1

View Full Paper

Ask AI

Bookmark

Implication

Analytical cross-sectional study finds high thrombotic risk linked to decreased coagulation inhibitors in sickle cell patients, indicating inflammation’s role.

The Natural Coagulation Inhibitors, Inflammation, and Thrombotic Risk in Sickle Cell Patients in Cameroon, an Analytical Cross-Sectionnal Study

Discussion

Member takes

Implication

Key Points

Cite This Study

The Natural Coagulation Inhibitors, Inflammation, and Thrombotic Risk in Sickle Cell Patients in Cameroon, an Analytical Cross-Sectionnal Study

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider